Protagonist Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $7,437 | $4,712 | $5,546 | $28,321 |
Gross Profit | 7,061 | 4,712 | 5,546 | 28,321 |
EBITDA | -43,342 | -38,978 | -41,737 | -19,071 |
EBIT | -43,718 | -39,339 | -42,041 | -19,310 |
Net Income | -44,384 | -39,339 | -34,771 | -11,655 |
Net Change In Cash | 7,437 | 4,712 | 5,546 | 28,321 |
Free Cash Flow | -35,529 | -2,025 | -29,593 | 124,818 |
Cash | 128,390 | 113,713 | 168,543 | 139,653 |
Basic Shares | 63,573 | 63,772 | 63,511 | 62,964 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $46,016 | $434,433 | $60,000 | $26,581 |
Gross Profit | 44,791 | 434,433 | 60,000 | 26,581 |
EBITDA | -128,086 | 253,669 | -90,340 | -128,004 |
EBIT | -129,311 | 252,843 | -93,652 | -131,373 |
Net Income | -130,149 | 275,188 | -78,955 | -123,413 |
Net Change In Cash | 46,016 | 434,433 | 60,000 | 26,581 |
Cost of Revenue | 2,169 | |||
Free Cash Flow | 56,081 | 182,797 | -70,845 | -108,932 |
Cash | 128,390 | 97,249 | 186,727 | 125,744 |
Basic Shares | 63,573 | 65,078 | 56,763 | 49,042 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.69 |
2025-09-30 | -$0.62 |
2025-06-30 | -$0.55 |
